Advertisement

Azathioprine

  • David Kanel
  • Barry Bresnihan
Part of the Progress in Inflammation Research book series (PIR)

Abstract

Azathioprine is a synthetic purine analogue — the 1-methyl-4-nitro-5-imidazolyl derivative of thioguanine. The principal metabolite of azathioprine is 6-mercaptopurine and this is metabolised by hypoxanthine guanine phosphoribosyl transferase (HGPRT) to produce the active metabolites thioinosinic and thioguanylic acid. These metabolites inhibit intracellular function by interfering with adenine and guanine ribonucleotide production through suppression of inosinic acid synthesis [1]. These effects result in downregulation of actively proliferating cells with a particular effect on bone marrow.

Keywords

Rheumatoid Arthritis Xanthine Oxidase TPMT Activity Established Rheumatoid Arthritis Hypoxanthine Guanine Phosphoribosyl Transferase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Elion GB (1989) The purine path to chemotherapy. Science 244(4900): 41–47CrossRefPubMedGoogle Scholar
  2. 2.
    Trotter JL, Rodey GE, Gebel HM (1982) Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med 306(6): 365–366PubMedGoogle Scholar
  3. 3.
    Bacon PA, Salmon M (1987) Modes of action of second-line agents. Scand J Rheumatol Suppl 64: 17–24Google Scholar
  4. 4.
    Crilly A, Mclnnes IB, Capell HA, Madhok R (1994) The effect of azathioprine on serum levels of interleukin 6 and soluble interleukin 2 receptor. Scand J Rheumatol 23(2): 87–91CrossRefPubMedGoogle Scholar
  5. 5.
    Huskisson EC (1984) Azathioprine. Clin Rheum Dis 10(2): 325–332PubMedGoogle Scholar
  6. 6.
    Lennard L, Van Loon JA, Weinshilboum RM (1989) Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46(2): 149–154PubMedGoogle Scholar
  7. 7.
    Stolk JN, Boerbooms AM, de Abreu RA, de Koning DG, van Beusekom HJ, Muller WH, van de Putte LB (1998) Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 41(10): 1858–1866CrossRefGoogle Scholar
  8. 8.
    Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM (1998) Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129(9): 716–718PubMedGoogle Scholar
  9. 9.
    Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P (2000) Genotypic analysis of thiopurine S-methyl-transferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118(6): 1025–1030CrossRefPubMedGoogle Scholar
  10. 10.
    Marra CA, Esdaile JM, Anis AH (2002) Practical pharmacogenetics: The cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 29(12): 2507–2512PubMedGoogle Scholar
  11. 11.
    Seidman EG, Furst DE (2002) Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine. J Rheumatol 29(12): 2484–2487PubMedGoogle Scholar
  12. 12.
    Lennard L (1998) Clinical implications of thiopurine methyltransferase—optimization of drug dosage and potential drug interactions. Ther Drug Monit 20(5): 527–531CrossRefPubMedGoogle Scholar
  13. 13.
    Ragab AH, Gilkerson E, Myers M (1974) The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 34(9): 2246–2249PubMedGoogle Scholar
  14. 14.
    Levy J, Paulus HE, Barnett EV, Sokoloff M, Bangert R, Pearson CM (1972) A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 15(1): 116–117Google Scholar
  15. 15.
    Urowitz MB, Gordon DA, Smythe HA, Pruzanski W, Ogryzio MA (1973) Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum 16(3): 411–418CrossRefPubMedGoogle Scholar
  16. 16.
    Hunter T, Urowitz MB, Gordon DA, Smythe HA, Ogryzio MA (1975) Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum 18(1): 15–20CrossRefPubMedGoogle Scholar
  17. 17.
    Cade R, Stein G, Pickering M, Schlein E, Spooner G (1976) Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med J 69(4): 388–392PubMedGoogle Scholar
  18. 18.
    Mason M, Currey HL, Barnes CG, Dunne JF, Hazleman BL, Strickland ID (1969) Azathioprine in rheumatoid arthritis. Br Med J 1(641): 420–422CrossRefPubMedGoogle Scholar
  19. 19.
    Woodland J, Chaput de Saintonge DM, Evans SJ, Sharman VL, Currey HL (1981) Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo. Ann Rheum Dis 40(4): 355–359CrossRefPubMedGoogle Scholar
  20. 20.
    Suarez-Almazor ME, Spooner C, Beiseck E (2000) Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 4: CD001461PubMedGoogle Scholar
  21. 21.
    Currey HL, Harris J, Mason RM, Woodland J, Beveridge T, Roberts CJ, Vere DW, Dixon AS, Davies J, Owen-Smith B (1974) Comparison of azathioprine, cyclophos-phamide, and gold in treatment of rheumatoid arthritis. Br Med J 3(5934): 763–766CrossRefPubMedGoogle Scholar
  22. 22.
    Dwosh IL, Stein HB, Urowitz MB, Smythe HA, Hunter T, Ogryzio MA (1977) Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum 20(2): 685–692CrossRefPubMedGoogle Scholar
  23. 23.
    Berry H, Liyanage SP, Durance RA, Barnes CG, Berger LA, Evans S (1976) Azathioprine and penicillamine in treatment of rheumatoid arthritis: a controlled trial. Br Med J 1(6017): 1052–1054CrossRefPubMedGoogle Scholar
  24. 24.
    Halberg P, Bentzon MW, Crohn O, Gad I, Halskov O, Heyn J, Ingemann M, Junker P, Lorenzen I, Moller I et al (1984) Double-blind trial of levamisole, penicillamine and azathioprine in rheumatoid arthritis. Clinical, biochemical, radiological and scintigraphic studies. Dan Med Bull 31(5): 403–409PubMedGoogle Scholar
  25. 25.
    Ahern MJ, Harrison W, Hollingsworth P, Bradley J, Laing B, Bayliss C (1991) A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust NZ J Med 21(6): 844–849Google Scholar
  26. 26.
    Kruger K, Schattenkirchner M (1994) Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis — results of a double-blind multicentre study. Clin Rheumatol 13(2): 248–255PubMedGoogle Scholar
  27. 27.
    Forre O, Bjerkhoel F, Salvesen CF, Berg KJ, Rugstad HE, Saelid G, Mellbye OJ, Kass E. (1987) An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 30(1): 88–92CrossRefPubMedGoogle Scholar
  28. 28.
    Hamdy H, McKendry RJ, Mierins E, Liver JA (1987) Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial. Arthritis Rheum 30(4): 361–368CrossRefPubMedGoogle Scholar
  29. 29.
    Arnold MH, O’Callaghan J, McCredie M, Beller EM, Kelly DE, Brooks PM (1990) Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study. Br J Rheumatol 29(2): 120–125CrossRefPubMedGoogle Scholar
  30. 30.
    Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Mulder J, Rasker JJ et al (1991) Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. Arthritis Rheum 34(8): 961–972CrossRefPubMedGoogle Scholar
  31. 31.
    Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R (1995) Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. Arthritis Rheum 38(12): 1799–1806CrossRefPubMedGoogle Scholar
  32. 32.
    Csuka M, Carrera GF, McCarty DJ (1986) Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A followup study. JAMA 255(17): 2315–2319CrossRefPubMedGoogle Scholar
  33. 33.
    Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32(5): 651–662PubMedGoogle Scholar
  34. 34.
    Singh G, Fries JF, Spitz P, Williams CA (1989) Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 32(7): 837–843PubMedGoogle Scholar
  35. 35.
    Penn I (1990) Cancers complicating organ transplantation. N Engl J Med 323(25): 1767–1779PubMedCrossRefGoogle Scholar
  36. 36.
    Silman AJ, Petrie J, Hazleman B, Evans SJ (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47(12): 988–992CrossRefPubMedGoogle Scholar
  37. 37.
    Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41(12): 1367–1374CrossRefGoogle Scholar
  38. 38.
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39(5): 723–731CrossRefGoogle Scholar
  39. 39.
    Kerstens PJ, Boerbooms AM, Jeurissen ME, de Graaf R, Mulder J, van de Putte LB (2000) Radiological and clinical results of longterm treatment of rheumatoid arthritis with methotrexate and azathioprine. J Rheumatol 27(5): 1148–1155PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • David Kanel
    • 1
  • Barry Bresnihan
    • 2
  1. 1.School of Clinical Medical Sciences (Rheumatology)University of Newcastle, Framlington PlaceNewcastle upon TyneUK
  2. 2.Department of RheumatologySt. Vincent’s University HospitalDublinIreland

Personalised recommendations